Pfizer Inc (PFE)

PFE (NYSE:Drugs)
$29.96
neg -0.14
-0.47%
Today's Range: 29.95 - 30.49 | PFE Avg Daily Volume: 27,176,900
Last Update: 07/29/14 - 1:16 PM EDT
Volume: 19,071,174
YTD Performance: -1.73%
Open: $30.33
Previous Close: $30.10
52 Week Range: $27.76 - $32.96
Oustanding Shares: 6,378,718,293
Market Cap: 192,573,505,266
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 4 6
Moderate Buy 1 1 2 2
Hold 4 4 3 2
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.08 2.08 2.15 1.86
Latest Dividend: 0.26
Latest Dividend Yield: 3.44%
Dividend Ex-Date: 07/30/14
Price Earnings Ratio: 18.41
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
18.41 9.60 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.05% 2.49% 55.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue -12.50 -0.24 -0.09
Net Income 51.20 0.38 0.11
EPS 64.40 2.14 0.46
Earnings for PFE:
EBITDA 22.78B
Revenue 51.58B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $0.56 $0.55 $2.25 $2.26
Number of Analysts 7 6 11 10
High Estimate $0.58 $0.57 $2.31 $2.38
Low Estimate $0.55 $0.53 $2.19 $2.15
Prior Year $0.56 $0.58 $2.22 $2.25
Growth Rate (Year over Year) 0.77% -5.46% 1.39% 0.32%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

This Morning's Market Setup Real Money Pro($)

Where it began.
Bearish
Jul 28, 2014 | 7:56 AM EDT
PFE was downgraded to Market Perform, BMO Capital said. $31 price target. Company has limited growth prospects.
If you insist on playing it, recognize the 50/50 nature of the scenario.
If you're worried about these moves, it's time to cash out.
Instead, in light of recent action, we should be extremely cautious.
A wave of M&A in the health sector makes sense.
Is there a case for these laggards in the Dow's jaunt to 17,000?

In Complacent Territory Real Money Pro($)

I see no reason to be a buyer or an aggressive shorter.
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.
Update
Jun 11, 2014 | 7:24 AM EDT
Goldman Sachs Healthcare Conference (Day 2 of 3) - 06/10/14 - 06/12/14 Los Angeles, CA

Columnist Conversations

Lang:
Going to be some big fireworks this week but we got it kick-started yesterday with some calls on WYNN, managin...
This one has met a minor target already, the next target comes in at 119.91-120.03, then 121.53. Trail up sto...
Katz:
ETN reported their earnings earlier today and just finished their quarterly conference call. Earnings were in...
Dollar call buyer in Dollar Tree. With shares near morning lows of $54.03 a buyer paid $1 for more than 3500 A...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.